Business Wire

smartTrade Announces Strategic Investment from TA alongside CEO and Management

Share

smartTrade Technologies (“smartTrade”), a leading global provider of multi-asset electronic trading and payments platforms, today announced a strategic investment from TA Associates (“TA”), a leading global private equity firm. David Vincent, CEO and Co-Founder of smartTrade, and the broader management team, would invest alongside TA at closing, reinforcing their shared commitment to the company’s future.

Headquartered in Aix-en-Provence, France, with subsidiaries in London, Paris, Geneva, New York, Toronto, Tokyo and Singapore, smartTrade empowers customers to grow their electronic trading and payments business through secure, cost-efficient and technologically advanced end-to-end SaaS solutions. TA’s investment would support continued product innovation, geographic expansion and scalable growth, with a particular emphasis on AI-driven solutions and deployment flexibility.

Upon completion of the transaction, Hg, a leading investor in European and transatlantic software and services businesses, would fully exit its majority investment in smartTrade. Closing of the transaction will be subject to customary workers’ council consultation process under applicable laws.

“Our customers have always been our North Star and this partnership with TA will enhance our ability to serve them with innovative trading and payments solutions. My decision to invest alongside the management team and TA underscores our shared belief in smartTrade’s trajectory,” said David Vincent, CEO & Co-Founder of smartTrade. “We're grateful to Hg for their strategic support over the past five years. During that time, we doubled our revenue, executed our first acquisition which strengthened our presence in North America, and laid the foundation for scalable growth. Looking ahead, we are committed to driving the next wave of client-centric innovation, including accelerated AI adoption and greater flexibility in hosting and execution, to meet our customers’ evolving needs."

“smartTrade has firmly established itself at the forefront of electronic trading and payments technology. We believe the company’s market-leading solutions, culture of innovation and unwavering commitment to client success have positioned it well for continued growth,” said Max Cancre, Managing Director at TA. “We look forward to partnering with David and the whole smartTrade team as they continue to scale globally and drive further advancements for the capital markets industry,” added Morgan Seigler, Managing Director at TA.

“We’ve worked in close partnership with smartTrade since 2020, helping to strengthen its position as the best-in-class modern trading and payments technology vendor. We thank David Vincent and his team for their impressive execution and continued focus on innovation, and we wish them well in their next phase of growth,” said Sebastien Briens, Partner at Hg.

Terms of the transaction are not disclosed. smartTrade was advised by Arma Partners. Houlihan Lokey and Deutsche Bank were advisers to TA Associates.

About TA

TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries – technology, healthcare, financial services, consumer and businesses services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has more than 150 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com.

About Hg

Hg supports the building of sector-leading enterprises that supply businesses with critical software applications or workflow services, delivering a more automated workplace for their customers. This industry is characterised by digitization trends that are in early stages of adoption and are set to transform the workplace for professionals over decades to come.

Hg’s support combines deep end-market knowledge with world class operational resources, together providing compelling support to entrepreneurial leaders looking to scale their business – businesses that are well invested, enduring and serve their customers well.

With a vast European network and strong presence across North America, Hg’s 400 employees and around $75 billion in funds under management support a portfolio of around 50 businesses, worth over $160 billion aggregate enterprise value, with around 115,000 employees, consistently growing revenues at more than 20% annually.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403011693/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release

POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base

Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release

Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,

Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release

Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of

Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release

New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou

Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release

The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye